ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Impax in hot water for 'pay-for-delay' deal on Endo painkiller Opana ER, feds say
April 02, 2019The Federal Trade Commission has been cracking down on “pay-for-delay" deals across pharma, and Impax …… -
Struggling Endo's write-downs pass $5B for 2017 thanks to Opana, mesh, restructuring
August 09, 2017In Feburary 2017, Endo took a huge $3.5 billion write-down—but that wouldn’t be just it for the year. -
FDA Requests Removal of Opana ER for Risks Related To Abuse
June 12, 2017The U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concer
Pharma Sources Insight January 2025
